HBD-3 vs Mifamurtide
Head-to-head comparison of HBD-3 (Human Beta-Defensin 3) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HBD-3 | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Beta-Defensin 3 | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | 5158 Da | N/A |
| Half-Life | Minutes to hours; protease-sensitive | 2-4 h |
| Amino Acids | 45 | N/A |
| Typical Dose | Research use only; no approved human dose | 2 mg/m2 |
| Route | Topical / Intranasal / Research parenteral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 380 | 150 |
| Research Status | Pre-clinical | Clinical |
HBD-3 Benefits
- ✓strong antimicrobial activity
- ✓skin and mucosal defense
- ✓innate immune signaling modulation
- ✓wound-healing support
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
HBD-3 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
HBD-3 Side Effects
- ⚠cell toxicity at high concentrations
- ⚠rapid proteolysis
- ⚠inflammatory activation in some contexts
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
HBD-3
Human beta-defensin 3 has been examined in numerous in vitro and animal studies for antimicrobial and immunomodulatory activity. Research suggests it can help defend barrier tissues while influencing cytokine networks, chemotaxis, and epithelial repair.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.